Eric Dube, Travere Therapeutics CEO

Tra­vere miss­es pri­ma­ry end­point in PhI­II for rare kid­ney dis­ease but the com­pa­ny is still con­sid­er­ing a 'path for­ward'

Tra­vere Ther­a­peu­tics’ drug sparsen­tan didn’t hit the pri­ma­ry end­point in a Phase III study in a rare kid­ney dis­ease, but nei­ther the com­pa­ny nor an­a­lysts have writ­ten it off as a com­plete fail­ure.

The study looked at sparsen­tan in fo­cal seg­men­tal glomeru­loscle­ro­sis (FS­GS), a rare kid­ney dis­ease that leads to scar­ring of the kid­ney, re­sult­ing in pro­tein­uria and rapid de­cline in kid­ney func­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.